Serum serotonin concentration in lean and obese dogs with myxomatous mitral valve disease

Abstract

Abstract:The aim of the present study is to investigate the potential influence of obesity as a factor in 5-hydroxytryptamine (5-HT) concentration in myxomatous mitral valve disease (MMVD) dogs. Fifty-five client-owned dogs were enrolled in a randomized trial. Dogs were classified by echocardiography into healthy (control), mild, and moderate to severe MMVD groups. Each group was subclassified by using a 9-point body condition score (BCS); lean (BCS 5-6/9) and obese groups (BCS 7.5-9/9). Dogs with moderate to severe MMVD had lower serotonin (5-HT) concentrations than the control group (p = 0.03). Dogs with moderate to severe MMVD (p = 0.017) had lower serum 5-HT concentrations than the control group in the obese group (BCS 7.5-9/9). Significant difference was found between the lean and obese groups (p = 0.015) which are not consider severe in the MMVD group. These results suggested that 5-HT concentration was decreased with the increasing severity of MMVD, and obesity might be taken into consideration when interpreting the serotonin concentration in MMVD dogs.

Pulmonary Hypertension Secondary to Myxomatous Mitral Valve Disease in Dogs: Current Insights into the Histological Manifestation and Its Determining Factors

“…A negative correlation between thrombocytic SRT and increasing plasma and serum SRT levels has also been described in humans. Due to the evidenced effects of SRT, most authors consider SRT to be one of the factors causing the development of MMVD [131][132][133][134], however, recent studies have not shown a clear role of SRT pathway gene expression in the development of PH in dogs, but have indicated increased protein synthesis of tryptophan hydroxylase 1 (TPH-1) and 5-hydroxytryptamine (serotonin) receptor 2a (5-HTR2A) in the MMVD and MMVD + PH states relative to the control group [97].…”